Medicare Coverage Ozempic 2026 What Changed

Medicare Coverage of Ozempic in 2026: What Changed and What It Means for Your Patients

If you prescribe Ozempic for Medicare beneficiaries, 2026 is the year everything shifts. The Inflation Reduction Act’s Part D redesign slashes out-of-pocket costs, but new coverage restrictions and potential CMS policy changes create a complex landscape. This guide delivers the specific data, rule changes, and actionable strategies you need to navigate Medicare coverage of Ozempic in 2026.

We cover the $2,000 out-of-pocket cap, the game-changing potential of a new National Coverage Determination for obesity, step therapy updates, and the critical differences between Original Medicare and Medicare Advantage. By the end, you will know exactly how to determine coverage, estimate costs, and handle denials for your patients.

The Inflation Reduction Act’s Part D Redesign: The $2,000 Cap Changes Everything

Starting January 1, 2026, the Inflation Reduction Act (IRA) fundamentally restructures Medicare Part D. The most impactful change for Ozempic prescribers is the new out-of-pocket maximum: $2,000 per year. In 2025, the cap was $3,250, and before the IRA, some patients faced $12,000 or more annually for Ozempic alone.

For a patient taking Ozempic at a list price of approximately $1,000 per month, the annual cost without insurance would be $12,000. Under the 2026 cap, their maximum out-of-pocket expense is $2,000—a savings of up to 83%. However, this cap applies only to covered drugs. If Ozempic is not on a patient’s Part D formulary, the cap offers no benefit.

How the Catastrophic Phase Was Eliminated

Before 2026, Medicare Part D had a coverage gap (the “donut hole”) and a catastrophic phase where patients paid 5% of drug costs. The IRA eliminates the catastrophic phase entirely. Once a patient reaches $2,000 in out-of-pocket spending, their Part D plan covers 100% of drug costs for the remainder of the year. This is a structural change that directly benefits patients on high-cost drugs like Ozempic.

For providers, this means a patient who previously abandoned therapy due to high monthly copays in the catastrophic phase now has predictable, capped costs. Adherence rates for GLP-1s historically drop by 15–20% when patients enter the catastrophic phase. The new cap should significantly improve persistence.

Will Medicare Cover Ozempic for Weight Loss in 2026? The CMS NCD Question

This is the most critical question for 2026, and the answer remains unsettled. As of May 2026, Medicare Part D covers Ozempic only for Type 2 diabetes mellitus (T2DM). The Social Security Act explicitly excludes coverage for weight loss drugs under Part D. However, a major policy shift is under active consideration.

In 2024, CMS issued a proposed National Coverage Determination (NCD) that would allow coverage of GLP-1s like Ozempic for obesity without T2DM, reinterpreting “obesity as a disease” rather than a cosmetic condition. That proposed rule was never finalized. In early 2026, CMS re-opened the comment period, signaling a potential final rule by late 2026. If finalized, this would unlock coverage for an estimated 10 million Medicare beneficiaries with obesity—roughly 30% of the program’s population.

Current Coverage Status (May 2026)

As of this writing, CMS has not issued a final NCD. Therefore, Medicare Part D plans are not required to cover Ozempic for weight loss alone. Some plans may voluntarily cover it for obesity if the patient also has prediabetes or cardiovascular disease, but this is inconsistent. The only guaranteed pathway to coverage remains a diagnosis of T2DM.

For patients with cardiovascular disease (CVD) but no diabetes, Ozempic’s FDA-approved indication for reducing major adverse cardiovascular events (MACE) does not automatically trigger Medicare coverage. Most Part D plans still require a T2DM diagnosis for formulary inclusion.

Step Therapy and Prior Authorization Changes in 2026

Medicare Part D plans are tightening their formularies for GLP-1s in 2026. Expect more aggressive step therapy and prior authorization (PA) requirements. Data from 2024 shows 22% of Ozempic claims under Medicare Part D were denied at initial submission. That rate is projected to rise to 25–28% in 2026 as plans respond to the IRA’s cost pressures.

New Step Therapy Rules

Most Part D plans now require patients to fail metformin and an SGLT2 inhibitor (e.g., Jardiance) before covering Ozempic. This “triple-step” protocol is more restrictive than the previous “metformin-first” approach. If your patient has not tried and failed an SGLT2, their Ozempic claim will be rejected.

For patients with contraindications to metformin or SGLT2s (e.g., eGFR <30 mL/min), you must document this explicitly in the prior authorization. Plans are increasingly requiring lab evidence, not just clinical notes.

Updated Prior Authorization Criteria

In 2026, many Part D plans have added new PA requirements for Ozempic:

• HbA1c documentation: Must show baseline HbA1c ≥7.0% (or ≥6.5% with complications).
• BMI requirement: Some plans now require BMI ≥27 kg/m² (overweight) or ≥30 kg/m² (obese), even for T2DM patients.
• Failure of alternatives: Documented trial of at least two other diabetes medications (metformin, SGLT2, DPP-4).
• Renal function: eGFR must be ≥30 mL/min for initiation.

If you encounter a denial, the appeals process under Medicare Part D has a 72-hour expedited timeline for urgent cases. Use it. The success rate for redeterminations (first-level appeals) is approximately 40% when proper documentation is submitted.

Biosimilar and Rebate Impact: Will Semaglutide Generics Change Coverage?

The patent for semaglutide (the active ingredient in Ozempic) expires in the U.S. in 2026. The first biosimilar is expected to launch early in the year. Based on the history of insulin biosimilars, prices could drop by 30–40%. This has direct implications for Medicare coverage.

If a biosimilar enters the market, Part D plans may move Ozempic to a higher formulary tier (Tier 4 or 5) and prefer the biosimilar on Tier 2 or 3. This will affect patient out-of-pocket costs, even under the $2,000 cap. For example, a Tier 5 drug may have a 25% coinsurance vs. a Tier 3 drug’s $47 copay.

IRA “Maximum Fair Price” Negotiations

Ozempic is not currently on the list of drugs selected for Medicare price negotiation under the IRA (the first 10 drugs were announced in 2024). However, if semaglutide biosimilars launch, CMS may add Ozempic to the negotiation list for 2027 or 2028. For 2026, the rebate structure remains unchanged, meaning plans still negotiate discounts directly with manufacturers.

Medicare Advantage vs. Original Medicare: Critical Differences in 2026

This is a major blind spot for many providers. Medicare Advantage (MA) plans operate under different rules than Original Medicare Part D. In 2025, only 38% of MA plans covered Ozempic for T2DM, compared to 55% for Original Medicare Part D. In 2026, that gap may widen.

Key takeaway: MA plans can use “medical necessity” restrictions that Original Medicare cannot. They may exclude Ozempic entirely if they deem it not medically necessary for a specific patient, even if the patient has T2DM. Always check the specific MA plan’s formulary before prescribing.

Decision Framework: Is Ozempic Covered for Your Patient?

Use this step-by-step framework to determine coverage for any Medicare patient in 2026.

Step 1: Confirm Diabetes Diagnosis

Check the patient’s medical record for a confirmed T2DM diagnosis (ICD-10 code E11.9 or specific complication codes). Without T2DM, coverage is extremely unlikely unless a new CMS NCD is finalized mid-2026. If the patient has prediabetes (R73.03) or obesity (E66.9) alone, proceed with caution—most plans will deny.

Step 2: Identify Plan Type

Ask the patient: “Do you have Original Medicare with a standalone Part D plan, or a Medicare Advantage plan (e.g., Humana, Aetna, UnitedHealthcare)?” If MA, call the plan directly to verify Ozempic is on the 2026 formulary. If Original Medicare, check the plan’s formulary online or via Medicare.gov.

Step 3: Verify Prior Authorization Status

Even if Ozempic is on formulary, most plans require PA. Submit the PA with:

• HbA1c ≥7.0% (or ≥6.5% with complications)
• Documented failure of metformin and an SGLT2 (or contraindications)
• BMI documentation (≥27 or ≥30, depending on plan)
• eGFR ≥30 mL/min

Step 4: Estimate Out-of-Pocket Cost

Under the $2,000 cap, the maximum cost is fixed. But if the drug is on a high tier, monthly copays may be $150–$300. Use the plan’s cost-sharing calculator. If the patient has already spent $500 on other Part D drugs, they will hit the cap faster.

Comparison Table: Ozempic Coverage (2025 vs. 2026)

What About Compounded Semaglutide and Mounjaro?

Many patients ask about alternatives. Here is the 2026 Medicare landscape for other options.

Warning: Compounded semaglutide is not FDA-approved and is not covered by Medicare. Patients who choose it bear full cost and risk. If a biosimilar launches, it will be the preferred alternative.

Actionable Advice for Providers

Here is what you need to do now to secure coverage for your patients in 2026.

1. Submit Prior Authorizations Early

Do not wait for the patient to hit the pharmacy. Submit PAs in December 2025 or January 2026 for the new plan year. Include all required documentation upfront to avoid denials.

2. Document Contraindications Thoroughly

If a patient cannot take metformin (e.g., due to CKD) or an SGLT2 (e.g., due to recurrent UTIs), document this explicitly in the medical record. Include lab values and clinical notes. This is the most common reason for PA denials.

3. Monitor CMS NCD Updates

Bookmark the CMS NCD page and check monthly. If the obesity NCD is finalized, it will be a landmark change. Prepare to submit PAs for obesity-only patients immediately.

4. Educate Patients on the $2,000 Cap

Many patients do not know their costs are capped. Explain that their maximum annual spend is $2,000, which is far less than the $12,000 list price. This improves adherence.

5. Appeal Denials Aggressively

If a claim is denied, file a redetermination within 60 days. Use the expedited process (72 hours) if the patient’s health is at risk. Include a letter of medical necessity citing FDA indications and CMS guidelines.

FAQ: Medicare Coverage of Ozempic in 2026

The Bottom Line for 2026

Medicare coverage of Ozempic in 2026 is defined by two opposing forces: the IRA’s $2,000 out-of-pocket cap, which makes the drug more affordable, and tightening formulary restrictions, which may limit access. The potential CMS NCD for obesity coverage is the single biggest unknown—if finalized, it will transform the landscape for millions of patients.

For providers, the strategy is clear: document thoroughly, submit prior authorizations early, and appeal denials aggressively. With the right approach, your patients can access Ozempic at a fraction of the previous cost. Stay informed, stay proactive, and use the data in this guide to navigate the changes effectively.